Proinflammatory cytokines and their membrane-bound receptors are altered in the lymphocytes of schizophrenia patients

Schizophrenia Research

Volumn 164, Issue 1-3, 2015, Pages 193-198

  Pandey, Ghanshyam N ^a   Ren, Xinguo ^a   Rizavi, Hooriyah S ^a   Zhang, Hui ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Gp130; IL 1R1; IL 1R2; IL 1RA; IL 1 ; IL 6; IL 6R; Lymphocytes; Proinflammatory cytokines; Schizophrenia; TNF ; TNFR1; TNFR2

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; GLYCOPROTEIN GP 130; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; NEUROLEPTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; LYMPHOCYTE; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADULT; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, CYTOKINE; RNA, MESSENGER; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84929266256     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.02.004     Document Type: Article

References (35)

1. Capuron L., Ravaud A., Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom. Med. 2001, 63(3):376-386.
2. Cheng Y.C., Chen C.C., Ho A.S., Chiu N.Y. Prolonged psychosis associated with interferon therapy in a patient with hepatitis C: case study and literature review. Psychosomatics 2009, 50(5):538-542.
3. Crane C., Martin M., Johnston D., Goodwin G.M. Does depression influence symptom severity in irritable bowel syndrome? Case study of a patient with irritable bowel syndrome and bipolar disorder. Psychosom. Med. 2003, 65(5):919-923.
4. Dantzer R., Aubert A., Bluthe R.-M., Gheusi G., Cremona S., Laye S., Konsman J.P., Parnet P., Kelley K.W. Mechanisms of the behavioral effects of cytokines. Cytokines, Stress and Depression 1999, 83-105. Kluwer Academic/Plenum Publishers, New York. R. Dantzer, E.E. Wollman, R. Yirmiya (Eds.).
5. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int. J. Neuropsychopharmacol. 2011, 14(7):997-1012.
6. Dean B., Tawadros N., Scarr E., Gibbons A.S. Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J. Affect. Disord. 2010, 120(1-3):245-248.
7. Dean B., Gibbons A.S., Tawadros N., Brooks L., Everall I.P., Scarr E. Different changes in cortical tumor necrosis factor-alpha-related pathways in schizophrenia and mood disorders. Mol. Psychiatry 2013, 18(7):767-773.
8. Dinarello C.A. Cytokines as mediators in the pathogenesis of septic shock. Curr. Top. Microbiol. Immunol. 1996, 216:133-165.
9. Drexhage R.C., Knijff E.M., Padmos R.C., Heul-Nieuwenhuijzen L., Beumer W., Versnel M.A., Drexhage H.A. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev. Neurother. 2010, 10(1):59-76.
10. Drexhage R.C., van der Heul-Nieuwenhuijsen L., Padmos R.C., van Beveren N., Cohen D., Versnel M.A., Nolen W.A., Drexhage H.A. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int. J. Neuropsychopharmacol. 2010, 13(10):1369-1381.
11. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav. Immun. 2006, 20(6):532-545.
12. Fineberg A.M., Ellman L.M. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol. Psychiatry 2013, 73(10):951-966.
13. Girgis R.R., Kumar S.S., Brown A.S. The cytokine model of schizophrenia: emerging therapeutic strategies. Biol. Psychiatry 2014, 75(4):292-299.
14. Hope S., Melle I., Aukrust P., Steen N.E., Birkenaes A.B., Lorentzen S., Agartz I., Ueland T., Andreassen O.A. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord. 2009, 11(7):726-734.
15. Hope S., Ueland T., Steen N.E., Dieset I., Lorentzen S., Berg A.O., Agartz I., Aukrust P., Andreassen O.A. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr. Res. 2013, 145(1-3):36-42.
16. Hosoda S., Takimura H., Shibayama M., Kanamura H., Ikeda K., Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin. Neurosci. 2000, 54(5):565-572.
17. Kuno K., Matsushima K. The IL-1 receptor signaling pathway. J. Leukoc. Biol. 1994, 56(5):542-547.
18. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1995, 19(1):11-38.
19. Maes M., Meltzer H.Y., Bosmans E., Bergmans R., Vandoolaeghe E., Ranjan R., Desnyder R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 1995, 34(4):301-309.
20. McMahan C.J., Slack J.L., Mosley B., Cosman D., Lupton S.D., Brunton L.L., Grubin C.E., Wignall J.M., Jenkins N.A., Brannan C.I., et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J. 1991, 10(10):2821-2832.
21. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
22. Modabbernia A., Taslimi S., Brietzke E., Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol. Psychiatry 2013, 74(1):15-25.
23. Munkholm K., Brauner J.V., Kessing L.V., Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J. Psychiatr. Res. 2013, 47(9):1119-1133.
24. Munkholm K., Vinberg M., Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J. Affect. Disord. 2013, 144(1-2):16-27.
25. Na K.S., Jung H.Y., Kim Y.K. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 48:277-286.
26. Padmos R.C., Hillegers M.H., Knijff E.M., Vonk R., Bouvy A., Staal F.J., de Ridder D., Kupka R.W., Nolen W.A., Drexhage H.A. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 2008, 65(4):395-407.
27. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63(8):801-808.
28. Rose-John S. Interleukin-6 biology is coordinated by membrane bound and soluble receptors. Acta Biochim. Pol. 2003, 50(3):603-611.
29. Rose-John S., Scheller J., Elson G., Jones S.A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukoc. Biol. 2006, 80(2):227-236.
30. Rothe J., Gehr G., Loetscher H., Lesslauer W. Tumor necrosis factor receptors-structure and function. Immunol. Res. 1992, 11(2):81-90.
31. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., Mirnics K. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol. Psychiatry 2011, 16(7):751-762.
32. Sims J.E., Acres R.B., Grubin C.E., McMahan C.J., Wignall J.M., March C.J., Dower S.K. Cloning the interleukin 1 receptor from human T cells. Proc. Natl. Acad. Sci. U. S. A. 1989, 86(22):8946-8950.
33. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367(9504):29-35.
34. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3(7). (RESEARCH0034).
35. Zakharyan R., Boyajyan A. Inflammatory cytokine network in schizophrenia. World J. Biol. Psychiatry 2014, 15(3):174-187.